AbbVie Unusual Options Activity Flags Bearish Sentiment as Stock Slides Near 52-Week Lows

By TrendSpider Editor

AbbVie Inc. (ABBV) is drawing attention in the options market today, with a dominant put contract sweeping in at the $185 strike generating $614,215 in premium and representing the largest single block among three unusual contracts totaling $1,096,323 in combined options activity. Shares are trading

AbbVie Unusual Options Activity Flags Bearish Sentiment as Stock Slides Near 52-Week Lows

AbbVie Inc. (ABBV) is drawing attention in the options market today, with a dominant put contract sweeping in at the $185 strike generating $614,215 in premium and representing the largest single block among three unusual contracts totaling $1,096,323 in combined options activity. Shares are trading at $203.16, down 0.89% on the session, sitting closer to the 52-week low of $176.57 than the 52-week high of $244.81. The options flow suggests at least a portion of the market is positioning for continued downside over the near term.

Key Drivers of the ABBV Stock Move

The forward setup for AbbVie carries meaningful uncertainty. The stock has already shed significant ground from its 52-week high of $244.81, and today's dominant put flow indicates that some institutional players are not ruling out a further leg lower before mid-June. The June 18 expiration gives traders roughly six weeks for that thesis to play out, a window that could capture any macro or company-specific catalysts. AbbVie continues to navigate the post-Humira revenue transition, leaning on its immunology and oncology pipeline including Skyrizi and Rinvoq to fill the gap. Any updates on pipeline progression, competitive pressures in the immunology space, or broader pharmaceutical sector sentiment could serve as near-term price catalysts. The combination of a declining session, proximity to the lower end of the 52-week range, and a heavily weighted bearish options print makes this a setup worth monitoring closely in the days ahead.

ABBV Unusual Options Activity

Three unusual contracts were flagged today across ABBV, with flow skewing bearish by premium weight:

The put contract alone accounts for more than half of the $1,096,323 in total premium across all three contracts, and its volume-to-open-interest ratio of 278% confirms this is a fresh, aggressive position rather than a roll of an existing trade.

ABBV Seasonality

May and early June have historically represented a mixed-to-cautious period for large-cap pharmaceutical names, with sector rotation dynamics often weighing on defensive health care stocks heading into summer. A June 18 put expiration sits squarely in this seasonally softer window, which may add conviction behind the bearish positioning seen today.

ABBV Relative Performance

ABBV is down 0.89% on the session at $203.16, trading in the lower half of its 52-week range of $176.57 to $244.81. The stock remains roughly 17% below its 52-week high, underperforming relative to its peak valuation and suggesting that the broader recovery seen in some large-cap peers has not fully extended to AbbVie shares at this stage.